Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Multiple Sclerosis

Free Subscription 01.06.2026 1 Arch Phys Med Rehabil 2 BMC Neurol 2 Brain 1 Hum Immunol 1 J Immunol 1 J Neurol 4 Lancet 4 Mult Scler 2 Neurology 2 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Arch Phys Med Rehabil

1. GOVEROVER Y, Costa SL, Mark VW, Chiaravalloti ND, et al
   Evidence-Based Cognitive Rehabilitation for Persons with Multiple Sclerosis: An Updated Systematic Review 2016 to 2024.
   Arch Phys Med Rehabil. 2026 May 25:S0003-9993(26)00733.
   PubMed         Abstract available
   
   

   
   BMC Neurol

2. BAKR NM, Hashim NA, El-Eshmawy MA, El-Baz HA, et al
   Impact of genetic polymorphisms in the interleukin-18 and interleukin-21 genes on the risk and clinical outcomes of multiple sclerosis.
   BMC Neurol. 2026;26:355.
   PubMed         Abstract available
   
   
3. KANANI MM, Abolhassani S, Nazari F
   The role of health literacy in medication adherence among people living with multiple sclerosis: a cross-sectional study in Isfahan, Iran.
   BMC Neurol. 2026 May 25. doi: 10.1186/s12883-026-04985.
   PubMed         Abstract available
   
   

   
   Brain

4. TUR C
   High-efficacy therapy and progression independent of relapse and MRI activity in multiple sclerosis.
   Brain. 2026 May 28:awag175. doi: 10.1093.
   PubMed        
   
   
5. GRANBERG T
   The skull-meningeal axis: a new window into multiple sclerosis progression.
   Brain. 2026 May 28:awag177. doi: 10.1093.
   PubMed        
   
   

   
   Hum Immunol

6. SEDENO MONGE V, Santos Lopez G, Bautista Rodriguez E, Rosas Murrieta NH, et al
   Reduced socs2 expression and elevated IL-4/IL-23 levels in multiple sclerosis patients: Implications for immune dysregulation.
   Hum Immunol. 2026;87:111763.
   PubMed         Abstract available
   
   

   
   J Immunol

7. AKBAR I, Arokia Doss PMI, Patel PU, Surury B, et al
   Myelin antigen-specific effector CD8+ T cells induce chronic CNS autoimmunity in a CD4+ T cell-dependent manner.
   J Immunol. 2026;215:vkag107.
   PubMed         Abstract available
   
   

   
   J Neurol

8. PEGORINI C, Cattaneo D, Meotti M, Baglio F, et al
   Artificial intelligence for gait and balance in neurological disorders: a scoping review of clinical applications and technologies.
   J Neurol. 2026;273:346.
   PubMed         Abstract available
   
   

   
   Lancet

9. COCCO E
   Integrating peripheral immune control and brain health in the multiple sclerosis continuum.
   Lancet. 2026;407:2144-2146.
   PubMed        
   
   
10. SAMARASEKERA U
    Stephen Hauser: transforming treatment for multiple sclerosis.
    Lancet. 2026;407:2163.
    PubMed        
    
    
11. HAUSER SL, Giovannoni G, Montalban X, Oh J, et al
    Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.
    Lancet. 2026;407:2180-2194.
    PubMed         Abstract available
    
    
12. GIOVANNONI G, Airas L, Bove R, Cutter GR, et al
    Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis, including older patients and those with more advanced disease (ORATORIO-HAND): a multicentre, double-blind, randomised, placebo-controlled, phase 3b study.
    Lancet. 2026;407:2195-2207.
    PubMed         Abstract available
    
    

    
    Mult Scler

13. CHANG G, Nasr Z, Schoeps VA, Virupakshaiah A, et al
    Adenotonsillectomy is associated with increased risk and disease activity in pediatric-onset multiple sclerosis.
    Mult Scler. 2026 May 29:13524585261444244. doi: 10.1177/13524585261444244.
    PubMed         Abstract available
    
    
14. RUIZ-ALGUERO M, Ahmed SM, Zhu F, Zhao Y, et al
    Prescription drug dispensations 15 years before multiple sclerosis onset: A matched cohort study, British Columbia, Canada.
    Mult Scler. 2026 May 27:13524585261450813. doi: 10.1177/13524585261450813.
    PubMed         Abstract available
    
    
15. AMINI F, Everett K, Zhu F, Li P, et al
    Phenotyping healthcare use before pediatric-onset multiple sclerosis, including by sex and age: A matched cohort study.
    Mult Scler. 2026 May 22:13524585261445372. doi: 10.1177/13524585261445372.
    PubMed         Abstract available
    
    
16. BARBUTI E, Piervincenzi C, Baione V, Ojha A, et al
    Clinical, structural, and functional MRI features predicting PIRMA at 5-year follow-up in multiple sclerosis.
    Mult Scler. 2026 May 22:13524585261445318. doi: 10.1177/13524585261445318.
    PubMed         Abstract available
    
    

    
    Neurology

17. SHARMIN S, Roos I, Labauge PM, Filippi M, et al
    Use of High-Efficacy Therapy in Children With Multiple Sclerosis to Prevent Long-Term Disability.
    Neurology. 2026;106:e218056.
    PubMed         Abstract available
    
    
18. GOMBOLAY GY, Rubin JP
    Sometimes Kids Really Are Just Little Adults: Early Access to High-Efficacy Therapy Decreases Disability in Pediatric Multiple Sclerosis.
    Neurology. 2026;106:e218168.
    PubMed        
    
    

    
    PLoS One

19. GUALCO C, Grange E, Rotondi F, Salivetto M, et al
    Vocational rehabilitation for people with multiple sclerosis: A systematic scoping review of international evidence.
    PLoS One. 2026;21:e0350122.
    PubMed         Abstract available
    
    
20. PICHI F, Jimenez YP, Belletti M, Alsuwaidi A, et al
    Retinal macrophage-like cell activation and ganglion cell layer thinning are associated with disability and MRI lesion burden in multiple sclerosis.
    PLoS One. 2026;21:e0349679.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Multiple Sclerosis is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum